ADMA Biologics, Inc. (ADMA) stock analysis

ADMA · ADMA Biologics, Inc.

Latest recorded price: USD 13.47

Model-estimated fair value: USD 27.22. This assumption-based estimate is for general research and is not investment advice.

Sector and industry: Healthcare · Biotechnology

At $13.47, ADMA trades 50.5% below the model's base-case value of $27.22. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $20.40 in the conservative case and $35.42 in the optimistic case, with a valuation confidence score of 45/100. Fiscal 2025 figures: revenue growth 49.0%, free cash flow margin 5.5%, ROIC 27.6%. The model flags 1 risk signal for this company.

Similar companies in Healthcare